Literature DB >> 34988678

Effectiveness of early exercise on reducing skeletal muscle loss during preoperative neoadjuvant chemotherapy for esophageal cancer.

Tomohiro Ikeda1, Kazuhiro Noma2, Naoaki Maeda3, Shunsuke Tanabe3, Yoko Sakamoto4, Yoshimi Katayama1, Yasuhiro Shirakawa5, Toshiyoshi Fujiwara3, Masuo Senda1.   

Abstract

PURPOSE: To investigate if early exercise can help prevent skeletal muscle loss and improve the clinical outcomes of esophageal cancer patients receiving preoperative neoadjuvant chemotherapy (NAC).
METHODS: This was a single-center, retrospective observational cohort study of 110 patients with advanced esophageal cancer. We analyzed the effect of early exercise on the risk of skeletal muscle loss (defined as > 2.98%) during NAC and the subsequent clinical outcomes. Patients in the early exercise group (n = 71) started exercise therapy 8 days earlier than those the late exercise group (n = 39).
RESULTS: The median age of the patients was 65.4 years, the mean BMI was 21.1 kg/m2, and 92 (84%) of the 110 patients were men. Skeletal muscle loss occurred in 34% and 67% of the early and late exercise groups, respectively (p < 0.001). There was a lower risk of surgical site infection in the early exercise group (1% vs 16%, p = 0.021). Multivariate analysis revealed that early exercise reduced the risk of skeletal muscle loss (OR = 0.25, 95% CI 0.09-0.65, p = 0.006).
CONCLUSIONS: Our results suggest that early exercise reduces the risk of both skeletal muscle loss during NAC and subsequent surgical site infection in patients with esophageal cancer.
© 2022. The Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd.

Entities:  

Keywords:  Esophagus; Exercise; Neoadjuvant therapy; Skeletal muscle

Mesh:

Year:  2022        PMID: 34988678     DOI: 10.1007/s00595-021-02449-5

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.540


  4 in total

1.  Effects of in-hospital exercise on sarcopenia in hepatoma patients who underwent transcatheter arterial chemoembolization.

Authors:  Shunji Koya; Takumi Kawaguchi; Ryuki Hashida; Keisuke Hirota; Masafumi Bekki; Emiko Goto; Maiko Yamada; Masako Sugimoto; Saki Hayashi; Norihiro Goshima; Teruhito Yoshiyama; Takashi Otsuka; Ryosuke Nozoe; Ayu Nagamatsu; Dan Nakano; Tomotake Shirono; Shigeo Shimose; Hideki Iwamoto; Takashi Niizeki; Hiroo Matsuse; Hironori Koga; Hiroko Miura; Naoto Shiba; Takuji Torimura
Journal:  J Gastroenterol Hepatol       Date:  2018-12-16       Impact factor: 4.029

2.  Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.

Authors:  Toshiyasu Ojima; Mikihito Nakamori; Masaki Nakamura; Masahiro Katsuda; Keiji Hayata; Tomoya Kato; Junya Kitadani; Hirotaka Tabata; Akihiro Takeuchi; Makoto Iwahashi; Hiroki Yamaue
Journal:  Anticancer Res       Date:  2016-02       Impact factor: 2.480

Review 3.  Preoperative chemotherapy for resectable thoracic esophageal cancer.

Authors:  Biniam Kidane; Shaun Coughlin; Kelly Vogt; Richard Malthaner
Journal:  Cochrane Database Syst Rev       Date:  2015-05-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.